IL10 and cancer: In brief LAG-3 is able to enhance regulatory T-lymphocytes levels through IL-10, resulting in a significant increase of cancer cells immune escape (6); therefore LAG-3 it is considered a new target of great clinical interest in cancer immunotherapy (7).